Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
Primary Purpose
Prostate Cancer
Status
Terminated
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Hyperpolarized Pyruvate (13C)
Sponsored by
About this trial
This is an interventional diagnostic trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
- Men with bone-metastatic CRPC before starting the first dose of radium 223 therapy
- Laboratory requirements:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x109/L
- Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)
- Total bilirubin level ≤ 1.5 institutional upper limit of normal (ULN)
- ASAT and ALAT ≤ 2.5 ULN
- • Creatinine ≤ 1.5 ULN
- Albumin >25 g/L
- Eastern Cooperative Oncology Group Status of 0 or 1
Exclusion Criteria:
- Unable to give valid informed consent
- Contraindication for MRI as per Sunnybrook MRI questionnaire (Appendix 1).
- Claustrophobia
- Body mass index of less than 18.5 or greater than 32
- Congestive heart failure, a past or present medical history of clinically significant electrocardiogram (EKG) abnormalities, which may include QT prolongation, a family history of prolonged QT interval syndrome, or a myocardial infarction (MI) within the past 12 months with ensuing unstable EKG, or ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year
Sites / Locations
- Sunnybrook Health Sciences Centre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MRI w/ Hyperpolarized Pyruvate (13C)
Arm Description
"Hyperpolarization" of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI.
Outcomes
Primary Outcome Measures
Images of lactate, bicarbonate and pyruvate in patients with bone-metastatic CRPC measured by MRI
Secondary Outcome Measures
Full Information
NCT ID
NCT02844647
First Posted
June 13, 2016
Last Updated
March 27, 2023
Sponsor
Sunnybrook Health Sciences Centre
1. Study Identification
Unique Protocol Identification Number
NCT02844647
Brief Title
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
Official Title
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Terminated
Why Stopped
Lack of participants
Study Start Date
December 15, 2016 (Actual)
Primary Completion Date
March 23, 2023 (Actual)
Study Completion Date
March 23, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sunnybrook Health Sciences Centre
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A pilot study with a group of up to 10 men with CRPC about to embark on a 6-month course of treatment with radium 223. Study participants will undergo anatomical MR imaging combined with the new hyperpolarized MRI (1 hour exam) prior to treatment.
Detailed Description
"Hyperpolarization" of low natural abundance species such as 13C, offers the potential of extracting metabolic information by real-time imaging of biochemical reactions within the body. In this project, the investigators focus on prostate cancer, specifically late-stage disease, as management of these patients would benefit from a new imaging method that enables improved therapy selection, planning and monitoring.
For imaging the lactate distribution in bone-metastatic prostate cancer, 3D coverage of a large field-of-view is required in order to cover the vertebral column (the most common site of metastases). To enable this, the investigators have developed methods using a large-volume transmitter and multi-channel receiver system for 3-dimensional 13C metabolic imaging in these patients. The image resolution and encoding matrix were tailored to the required 3D coverage of the vertebral column.
At the end of this study, the investigators will have the methodology, hardware and clinical-research workflow needed to evaluate 13C-lactate imaging as a new tool to help patients with metastatic prostate cancer. The investigators would be the first in the world to apply 13C metabolic MRI to bone metastases. Although the investigators propose to study patients who are starting a 6-month course of treatment with radium 223, in this project, this proof-of-concept study may also lead to a larger clinical trial at different points in the treatment pathway, such as prior to deciding between treatment with cytotoxic agents versus drugs that target the androgen axis such as abiraterone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MRI w/ Hyperpolarized Pyruvate (13C)
Arm Type
Experimental
Arm Description
"Hyperpolarization" of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI.
Intervention Type
Other
Intervention Name(s)
Hyperpolarized Pyruvate (13C)
Intervention Description
MRI contrast agent
Primary Outcome Measure Information:
Title
Images of lactate, bicarbonate and pyruvate in patients with bone-metastatic CRPC measured by MRI
Time Frame
1 year
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men with bone-metastatic CRPC before starting the first dose of radium 223 therapy
Laboratory requirements:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x109/L
Hemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)
Total bilirubin level ≤ 1.5 institutional upper limit of normal (ULN)
ASAT and ALAT ≤ 2.5 ULN
• Creatinine ≤ 1.5 ULN
Albumin >25 g/L
Eastern Cooperative Oncology Group Status of 0 or 1
Exclusion Criteria:
Unable to give valid informed consent
Contraindication for MRI as per Sunnybrook MRI questionnaire (Appendix 1).
Claustrophobia
Body mass index of less than 18.5 or greater than 32
Congestive heart failure, a past or present medical history of clinically significant electrocardiogram (EKG) abnormalities, which may include QT prolongation, a family history of prolonged QT interval syndrome, or a myocardial infarction (MI) within the past 12 months with ensuing unstable EKG, or ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles Cunningham, PhD
Organizational Affiliation
Sunnybrook Research Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
We'll reach out to this number within 24 hrs